Tempus AI's Q2 2026 print, filed as a 10-Q on July 30, 2026, for the period ended June 30, 2026, delivered a headline EPS beat of meaningful magnitude — a reported loss of $0.04 against a consensus estimate of -$0.20 — yet the SEC-filed figures tell a materially different story: a net loss of $0.67 per share against total revenue of $730.6 million on a trailing basis, with the standalone quarter logging $382.5 million in revenue. The surface-level narrative of a momentum AI healthcare name finding its footing collides with an operating margin of -21.99% and a net margin of -16.46%, confirming that revenue scale is accumulating faster than the path to profitability is narrowing.
The Result
On a quarterly basis, Tempus AI reported revenue of $382.5 million, a figure that GuruFocus characterized as representing 22% year-over-year growth. The Benzinga consensus estimate for revenue implied a surprise of +0.01% — essentially in-line, though the framing of "beats estimates" in headline coverage obscures the precision of the alignment. The EPS result of -$0.04 versus the -$0.20 estimate produces an 80-percentage-point positive surprise on a per-share basis, a figure that commands attention but requires context: adjusted EPS metrics in AI-adjacent healthcare names routinely exclude stock-based compensation and restructuring charges at scale, and the SEC-filed trailing EPS of -$0.67 anchors the actual dilution reality.
Print Scorecard
| Metric | Actual | Estimate | Surprise % | Source |
|---|---|---|---|---|
| EPS (adjusted, Q2) | -$0.04 | -$0.20 | +80.0% | 10-Q filed 2026-07-30; Benzinga consensus |
| EPS (SEC trailing) | -$0.67 | — | — | 10-Q filed 2026-07-30 |
| Revenue (Q2) | $382,486,000 | ~$382,447,000 (implied) | +0.01% | 10-Q filed 2026-07-30; Benzinga consensus |
| SEC Revenue (trailing) | $730,602,000 | — | — | 10-Q filed 2026-07-30 |
| Operating Margin | -21.99% | N/A | — | 10-Q filed 2026-07-30 |
| Net Margin | -16.46% | N/A | — | 10-Q filed 2026-07-30 |
Narrative Test
The prevailing narrative entering this print centered on declining short interest — 33.94% short float coming in — interpreted by segments of the market as a sign of conviction building or at minimum of short covering providing a technical tailwind. The post-print short float reading of 30.66% confirms that covering did occur across the reporting window, and the +6.59% single-day price reaction on July 31 is consistent with a squeeze dynamic layered on top of the EPS beat. The characterization of the incoming narrative as retail-driven momentum, with a fair value gap assessment of -35.05%, is not contradicted by the print — it is complicated by it. The 80% EPS beat gives retail holders a legitimate data point to anchor conviction, but the operating margin of -21.99% and trailing net loss per share of $0.67 ensure that any institutional re-rating would require evidence of margin trajectory improvement rather than a single quarter's adjusted figure. The narrative has not been broken; it has been handed fuel that may sustain the pump while the structural deficit remains unresolved.
Forensic Dissection
The $382.5 million in quarterly revenue, representing 22% year-over-year growth per earnings call commentary cited by GuruFocus (July 30, 2026), is the headline asset in this print. Revenue acceleration in AI-enabled clinical data and genomics services is the core commercial thesis, and on that dimension the quarter delivered. The problem is what sits below the revenue line.
An operating margin of -21.99% on $382.5 million of revenue implies approximately $84.1 million in operating losses for the quarter. This is not a business in the final stages of burning toward breakeven — it is a business still consuming capital at scale while scaling its top line. The net margin of -16.46% implies approximately $62.9 million in net losses against quarterly revenue, suggesting that below-operating-line items provided some partial offset — potentially interest income on cash balances or favorable non-operating adjustments — but the order of magnitude of the loss is not trivial.
The absence of a reported gross margin figure is itself a data point. Gross margin disclosure is standard in healthcare technology earnings; its absence in the provided data may reflect segment reporting complexity, deferred cost recognition tied to long-term genomics service contracts, or simply a timing lag in analyst model reconciliation. This gap warrants direct investigation against the filed 10-Q statements.
The EPS beat of -$0.04 versus -$0.20 is arithmetically striking, but the SEC-filed trailing EPS of -$0.67 — representing the full historical dilution per share — suggests the adjusted figure excludes substantial non-cash charges. Stock-based compensation in AI-stage healthcare companies of this profile routinely runs at 15-25% of revenue; if that pattern holds here, the "beat" is largely a function of exclusion methodology rather than operational efficiency gains.
On guidance, no explicit forward figures were provided in the data available at publication. The absence of upward guidance revision in the context of a headline beat would represent a cautious management posture — or reflect continued uncertainty about the pace of payer contract conversion and genomics data monetization timing.
Watchlist — Four Items for the Next 30 Days
- Gross margin disclosure: The 10-Q filing should contain a full income statement breakdown; the first analytical priority is extracting and trending gross margin across at least three quarters to assess whether the revenue ramp is driving operating leverage or simply growing absolute losses at a proportional rate.
- Short float trajectory: At 30.66% post-print, TEM remains among the most heavily shorted names in the AI healthcare universe; any further decline in short interest toward the 25% range would signal a structural shift in institutional positioning rather than tactical covering.
- Stock-based compensation as a percentage of revenue: The gap between adjusted EPS of -$0.04 and SEC EPS of -$0.67 implies substantial non-cash charges; isolating SBC as a revenue percentage across Q1 and Q2 2026 will clarify whether the beat reflects operational improvement or accounting presentation.
- Q3 revenue guidance and payer contract announcements: The durability of 22% revenue growth depends on the conversion pipeline from pilot programs to recurring payer-reimbursed clinical data services; any announcements between now and the Q3 print will materially affect whether the growth rate is front-loaded or structural.
Tempus AI's Q2 print extended the revenue growth narrative with a technically valid EPS beat, but an operating margin of -21.99% and a trailing SEC net loss of $0.67 per share establish that the distance between commercial momentum and financial durability remains the central unresolved variable in this story.